Author + information
- Duk-Woo Park,
- Osung Kwon,
- Se Hun Kang,
- Jung-Bok Lee,
- Jung-Min Ahn,
- Cheol Hyun Lee,
- Do-Yoon Kang,
- Pil Hyung Lee,
- Soo-Jin Kang,
- Young-Hak Kim,
- Cheol Whan Lee,
- Seong-Wook Park and
- Seung-Jung Park
Data on the comparative effectiveness of contemporary drug-eluting stents (DES) in the unrestricted, real-world setting are limited.
From 7 stent-specific, prospective registries, 17,196 patients were analysed; 3,053 cobalt-chromium everolimus-eluting stent (CoCr-EES), 2,985 platinum-chromium EES (PtCr-EES), 2,922 Resolute zotarolimus-eluting stent (Re-ZES), 789 Biomatrix biolimus-eluting stent (Bi-BES), 1,907 Nobori biolimus-eluting stent (No-BES), 1,970 Xience Prime CoCr-EES (Pr-CoCr-EES), and 3,570 sirolimus-eluting stent (SES). The primary outcome was target-vessel failure (TVF); composite of cardiac death, target-vessel myocardial infarction, or target-vessel revascularization. Multiple treatment propensity score weighting was used.
The observed 3-year rates of TVF did not differ (CoCr-EES 9.8%, PtCr-EES 9.5%, Re-ZES 9.3%, Bi-BES 9.8%, No-BES 7.7%, Pr-CoCr-EES 10.4%, SES 10.2%; P=0.07). In multiple treatment propensity-score analysis, adjusted hazard ratios (HR) for TVF were similar in between-group comparisons (Figure), except for Re-ZES vs. CoCr-EES (reference) (HR, 1.26; 95% confidence interval [CI], 1.06-1.50, P=0.01) and No-BES vs. Re-ZES (reference) (HR, 0.76; 95% CI 0.61-0.94, P=0.01).
In this comparative effectiveness research using clinical practice registries, there were no significant between-group differences in the 3-year rates of TVF, except a higher risk of Re-ZES compared with CoCr-EES and No-BES.
Poster Hall, Hall A/B
Saturday, March 10, 2018, 10:00 a.m.-10:45 a.m.
Session Title: Interventional Cardiology: Coronary Interventions of Complex Lesions, Left Main Disease, BVS and Advanced Imagery
Abstract Category: 21. Interventional Cardiology: Coronary Intervention: Devices
Presentation Number: 1114-258
- 2018 American College of Cardiology Foundation